Oklahoma is one of the states in the US with the highest prevalence of diabetes, with 10% of the population affected. Diabetes is particularly prevalent among Native American communities, where it affects up to 40% of older individuals in some tribes. Thus, diabetes and its complications constitute a major threat to the working- age and older population, and confer an immense social and economic burden on Oklahoma. The goal of this COBRE is to enhance diabetes research in Oklahoma. In Phase I and Phase II, our COBRE achieved its milestones. All of the COBRE-supported Junior Investigators have received independent grants, including eight NIH R01 grants, two R21 grants, and multiple grants from foundations such as the American Diabetes Association and the American Heart Association. Five of our Junior Investigators have been promoted to Associate Professor, and three of them have received tenure thus far. In addition, because of their success in research, two of them received endowed chair positions. Between them, the Junior Investigators have published 207 peer-reviewed papers, 135 of which received support from COBRE-funded Cores. In collaboration with the College of Medicine, the COBRE has recruited three NIH R01-funded and 1 K99/R00-funded diabetes researchers into The University of Oklahoma Health Sciences Center (OUHSC). The COBRE-funded Cores have provided support and service to multiple PIs and supported their publications and NIH-funded grants, which enhanced diabetes research in Oklahoma. In Phase III of the COBRE program, we plan to sustain and augment these successes. We will continue supporting and mentoring Junior Investigators who graduated from the COBRE. We will expand and improve Core facilities to serve diabetes research in Oklahoma and complete transition of the COBRE-funded facilities into institutional research Cores. We will further increase the critical mass of diabetes research in Oklahoma by promoting recruitment of diabetes researchers into OUHSC. Moreover, we will continue promoting collaborative and translational research. These efforts should contribute to continuous growth of diabetes research to achieve our goal of becoming a NIH P30-funded Diabetes Research Center (DRC). This Center should greatly improve prevention and treatment of diabetes.

Public Health Relevance

Diabetes research is a strategic research area at OUHSC. This COBRE is to mentor junior diabetes researcher and improve infrastructure of diabetes research in Oklahoma. These COBRE efforts will greatly enhance diabetes research. These researches will lead to improved prevention and treatment of diabetes, benefiting diabetic patients.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Center Core Grants (P30)
Project #
1P30GM122744-01
Application #
9281482
Study Section
Special Emphasis Panel (ZGM1)
Program Officer
Gao, Hongwei
Project Start
2017-07-01
Project End
2022-06-30
Budget Start
2017-07-01
Budget End
2018-06-30
Support Year
1
Fiscal Year
2017
Total Cost
Indirect Cost
Name
University of Oklahoma Health Sciences Center
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
878648294
City
Oklahoma City
State
OK
Country
United States
Zip Code
73104
Wang, Bing; Li, Pui-Kai; Ma, Jian-Xing et al. (2018) Therapeutic Effects of a Novel Phenylphthalimide Analog for Corneal Neovascularization and Retinal Vascular Leakage. Invest Ophthalmol Vis Sci 59:3630-3642
Shin, Younghwa; Moiseyev, Gennadiy; Petrukhin, Konstantin et al. (2018) A novel RPE65 inhibitor CU239 suppresses visual cycle and prevents retinal degeneration. Biochim Biophys Acta Mol Basis Dis 1864:2420-2429
Chen, Jianglei; Fan, Jun; Wang, Shirley et al. (2018) Secreted Klotho Attenuates Inflammation-Associated Aortic Valve Fibrosis in Senescence-Accelerated Mice P1. Hypertension 71:877-885
Chen, Qian; Qiu, Fangfang; Zhou, Kelu et al. (2017) Pathogenic Role of microRNA-21 in Diabetic Retinopathy Through Downregulation of PPAR?. Diabetes 66:1671-1682
Vanlandingham, Phillip A; Nuno, Didier J; Quiambao, Alexander B et al. (2017) Inhibition of Stat3 by a Small Molecule Inhibitor Slows Vision Loss in a Rat Model of Diabetic Retinopathy. Invest Ophthalmol Vis Sci 58:2095-2105
Malechka, Volha V; Moiseyev, Gennadiy; Takahashi, Yusuke et al. (2017) Impaired Rhodopsin Generation in the Rat Model of Diabetic Retinopathy. Am J Pathol 187:2222-2231
Qiu, Fangfang; Liu, Zhen; Zhou, Yueping et al. (2017) Decreased Circulating Levels of Dickkopf-1 in Patients with Exudative Age-related Macular Degeneration. Sci Rep 7:1263
Pearsall, Elizabeth A; Cheng, Rui; Zhou, Kelu et al. (2017) PPAR? is essential for retinal lipid metabolism and neuronal survival. BMC Biol 15:113
Qiu, Fangfang; Matlock, Greg; Chen, Qian et al. (2017) Therapeutic Effects of PPAR? Agonist on Ocular Neovascularization in Models Recapitulating Neovascular Age-Related Macular Degeneration. Invest Ophthalmol Vis Sci 58:5065-5075
Deng, Guotao; Moran, Elizabeth P; Cheng, Rui et al. (2017) Therapeutic Effects of a Novel Agonist of Peroxisome Proliferator-Activated Receptor Alpha for the Treatment of Diabetic Retinopathy. Invest Ophthalmol Vis Sci 58:5030-5042

Showing the most recent 10 out of 12 publications